C1-inhibitor attenuates hyperacute rejection and inhibits complement, leukocyte and platelet activation in an ex vivo pig-to-human perfusion model

Immunopharmacology

Volumn 42, Issue 1-3, 1999, Pages 231-243

  Fiane, Arnt E ^a   Videm, Vibeke ^b   Johansen, Harald T ^c   Mellbye, Ove J ^a   Nielsen, Erik W ^d   Mollnes, Tom E ^d  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

^d NORDLAND HOSPITAL   (Norway)

Author keywords

Complement inhibition; Contact activation; Discordant model; Pig kidney xenograft; Xenotransplantation

Indexed keywords

BETA THROMBOGLOBULIN; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C1S INHIBITOR; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C4B; FIBRIN; HUMAN SERUM ALBUMIN; IMMUNOGLOBULIN G; MYELOPEROXIDASE; PADGEM PROTEIN; THROMBOSPONDIN;

ANIMAL TISSUE; COMPLEMENT ACTIVATION; COMPLEMENT INHIBITION; CONFERENCE PAPER; CONTROLLED STUDY; FEMALE; FIBRIN DEPOSITION; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY PERFUSION; LEUKOCYTE COUNT; LYMPHOCYTE ACTIVATION; MALE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; SWINE; THROMBOCYTE ACTIVATION; THROMBOCYTE COUNT;

EID: 0033041212     PISSN: 01623109     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0162-3109(99)00008-9     Document Type: Conference Paper

References (42)

1. Baldwin W.M. III, Pruitt S.K., Brauer R.B., Daha M.R., Sanfilippo F. Complement in organ transplantation. Contributions to inflammation, injury, and rejection. Transplantation. 59:1995;797-808.
2. Busch G.J., Kobayashi K., Hollenberg N.K., Birtch A.G., Colman R.W. Hyperacute renal allograft rejection in the primate. Intrarenal effects of heparin and associated net release of factor VIII activity and kallikrein activation. Am. J. Pathol. 80:1975;1-20.
3. Cholin S., Gerard N.P., Strang C.J., Davis A.E. III Biologic activity of a C2-derived peptide. Demonstration of a specific interaction with guinea pig lung tissues. J. Immunol. 142:1989;2401-2404.
4. Colman R.W. Significance of the regulation of plasma kallikrein by alpha 2 M. Ann. NY Acad. Sci. 737:1994;347-367.
5. Coppola L., Verrazzo G., Giunta R., Tirelli A. C1-Inhibitor (C1-INH) and platelet aggregation. Haematologica. 73:1988;155.
6. Dalmasso A.P. The complement system in xenotransplantation. Immunopharmacology. 24:1992;149-160.
7. Dalmasso A.P., Platt J.L. Prevention of complement-mediated activation of xenogeneic endothelial cells in an in vitro model of xenograft hyperacute rejection by C1-inhibitor. Transplantation. 56:1993;1171-1176.
8. Dalmasso A.P., Platt J.L. Potentiation of C1-inhibitor plus heparin in prevention of complement-mediated activation of endothelial cells in a model of xenograft hyperacute rejection. Transplant. Proc. 26:1994;1246-1247.
9. Davis A.E. III C1-Inhibitor and hereditary angioneurotic edema. Annu. Rev. Immunol. 6:1988;595-628.
10. De La Cadena R.A., Scott C.F., Colman R.W. Evaluation of a microassay for human plasma prekallikrein. J. Lab. Clin. Med. 109:1987;601-607.
11. Di Stefano R., Frosini F., Scavuzzo M., Ambrogi M., Fagiolini A., Ferrari M., Pelosi G., Mosca F. C1-inh and heparan sulfate can prevent discordant rejection. Transplant. Proc. 26:1994;1172-1173.
12. Di Stefano R., Carmellini M., Oleggini M., Palla R., Giovannini L., Scavuzzo M., Bellissima G., Mosca F. A study of pig kidneys to expand the organ pool. Transplant. Proc. 28:1996;130-131.
13. Fiane A.E., Videm V., Foerster A., Scholz T., Pedersen T.H., Karlsen H., Svennevig J.L., Geiran O.R., Aasen A.O., Mollnes T.E. An ex vivo perfusion model to evaluate hyperacute rejection in a discordant pig-to-human combination. Eur. Surg. Res. 30:1998;341-351.
14. Fiane A.E., Videm V., Mellbye O.J., Foerster A., Geiran O.R., Gladhaug I.P., Svennevig J.L., Mollnes T.E. Immunoglobulin prolongs survival of pig kidneys perfused ex vivo with human blood. Scand. J. Immunol. 47:1998;568-574.
15. Fiane, A.E., Mollnes, T.E., Videm, V., Hovig, T., Høgåsen, K., Mellbye, O.J., Spruce, L., Moore, W.T., Sahu, A., Lambris, J.D., 1999. Compstatin, a peptide inhibitor of C3, prolongs survival of ex vivo perfused xenografts. Xenotransplantation (in press).
16. Fure H., Nielsen E.W., Hack C.H., Mollnes T.E. A neoepitope-based enzyme immunoassay for quantification of C1-inhibitor in complex with C1r and C1s. Scand. J. Immunol. 46:1997;553-557.
17. Ghebrehiwet B., Peerschke E.I. The C1q-R participates in immunoregulation and signal transduction. Behring. Inst. Mitt. 93:1993;236-240.
18. Gustafson E.J., Schutsky D., Knight L.C., Schmaier A.H. High molecular weight kininogen binds to unstimulated platelets. J. Clin. Invest. 78:1986;310-318.
19. Harrison R.A. Human C1-inhibitor: improved isolation and preliminary structural characterization. Biochemistry. 22:1983;5001-5007.
20. Heckl-Östreicher B., Wosnik A., Kirschfink M. Protection of porcine endothelial cells from complement-mediated cytotoxicity by the human complement regulators CD59, C1-inhibitor, and soluble complement receptor type 1. Analysis in a pig-to-human in vitro model relevant to hyperacute xenograft rejection. Transplantation. 62:1996;1693-1696.
21. Henry M.L., Bendle M.D., Bryan B.A., Ferguson R.M. Neutrophils protect xenoendothelium in an ex vivo sequential cell perfusion model. Transplant. Proc. 26:1994;1161.
22. Herwald H., Morgelin M., Olsen A., Rhen M., Dahlback B., Muller-Esterl W., Bjørck L. Activation of the contact-phase system on bacterial surfaces - a clue to serious complications in infectious diseases. Nat. Med. 4:1998;298-302.
23. Häyry P., von Willebrand E., Parthenais E., Nemlander A., Soots A., Lautenschlager I., Alfoldy P., van Iwaarden F., Bouma B.N. Role of high molecular weight kininogen in contact activation. Semin. Thromb. Hemost. 13:1987;15-24.
24. Jakobs F.M., Davis E.A., White T., Sanfilippo F., Baldwin W.M. III Prolonged discordant xenograft survival by inhibition of the intrinsic coagulation pathway in complement C6-deficient recipients. J. Heart Lung Transplant. 17:1998;306-311.
25. Kaplan A.P., Joseph K., Shibayama Y., Reddigari S., Ghebrehiwet B., Silverberg M. The intrinsic coagulation/kinin-forming cascade: assembly in plasma and cell surfaces in inflammation. Adv. Immunol. 66:1997;225-272.
26. Karlsrud T.S., Buø L., Aasen A.O., Johansen H.T. Quantification of kininogens in plasma. A functional method based on the cysteine proteinase inhibitor activity. Thromb. Res. 82:1996;265-273.
27. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 227:1970;680-685.
28. Lappin D., Whaley K. Regulation of C1-inhibitor synthesis by interferons and other agents. Behring. Inst. Mitt. 84:1989;80-92.
29. Lawson J.H., Platt J.L. Molecular barriers to xenotransplantation. Transplantation. 62:1996;303-310.
30. Mollnes, T.E., 1997. Analysis of in vivo complement activation. In: Herzenberg, L.A., Weir, D.M., Herzenberg, L.A., Blackwell, C. (Eds.), Weir's Handbook of Experimental Immunology, 5th edn. Boston, Blackwell Science, pp. 78.1-78.8.
31. Nielsen E.W., Johansen H.T., Straume B., Mollnes T.E. Effect of time, temperature and additives on a functional assay of C1-inhibitor. J. Immunol. Methods. 173:1994;245-251.
32. 3 integrins (GPIIb-IIIa) and the expression of P-selectin and procoagulant activity. J. Exp. Med. 178:1993;579-587.
33. Platt J.L. The immunological barriers to xenotransplantation. Crit. Rev. Immunol. 16:1996;331-358.
34. Pruitt S.K., Baldwin W.M. III, Marsh H.C. Jr., Lin S.S., Yeh C.G., Bollinger R.R. The effect of soluble complement receptor type 1 on hyperacute xenograft rejection. Transplantation. 52:1991;868-873.
35. Saito H. Contact factors in health and disease. Semin. Thromb. Hemost. 13:1987;36-49.
36. Sims P.J., Wiedmer T. The response of human platelets to activated components of the complement system. Immunol. Today. 12:1991;338-342.
37. Sundsmo J.S., Fair D.S. Relationships among the complement, kinin, coagulation, and fibrinolytic systems. Springer Semin. Immunopathol. 6:1983;231-258.
38. Towbin H., Staehlin T., Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc. Natl. Acad. Sci. USA. 76:1979;4350-4354.
39. van Beaumont W. Evaluation of hemoconcentration from hematocrit measurements. J. Appl. Physiol. 32:1972;712-713.
40. van Iwaarden F., de Groot P.G., Sixma J.J., Berrettini M., Bouma B.N. High-molecular weight kininogen is present in cultured human endothelial cells: localization, isolation, and characterization. Blood. 71:1988;1268-1276.
41. Videm V., Fosse E., Mollnes T.E., Garred P., Svennevig J.L. Time for new concepts about measurement of complement activation by cardiopulmonary bypass? Ann. Thorac. Surg. 54:1992;725-731.
42. Wolbink G.J., Bollen J., Baars J.W., ten Berge R.J., Swaak A.J., Paardekooper J., Hack C.E. Application of a monoclonal antibody against a neoepitope on activated C4 in an ELISA for the quantification of complement activation via the classical pathway. J. Immunol. Methods. 163:1993;67-76.